Browsing Tag
biotechnology
76 posts
Curi Bio and Battelle partner to scale human-relevant neuromuscular testing platforms as FDA shifts toward animal-free drug development
Curi Bio and Battelle announce strategic partnership to commercialize neuromuscular junction testing technology, positioning for regulatory shift toward human-relevant drug development methods.
Why Hims & Hers Health’s decision to offer Grail’s Galleri test looks riskier after the U.K. NHS trial miss
Grail’s Galleri cancer test missed a major U.K. NHS trial goal just as Hims & Hers Health began offering it. Find out what this means for investors and screening strategy.
Why NervGen Pharma Corp’s Chief Financial Officer retirement matters more than it appears
NervGen Pharma Corp announces its Chief Financial Officer’s planned retirement. Find out what the leadership change signals for capital strategy and investors.
Ascletis Pharma advances ASC36 into clinical development, betting on oral amylin peptides for obesity
Ascletis Pharma Inc. moves ASC36 into clinical development, signalling a strategic push into oral amylin peptides for obesity. Find out what this means next.
Can Illumina’s SomaLogic takeover finally make multiomics scalable at pharma speed?
Illumina has acquired SomaLogic to deepen its proteomics and multiomics capabilities. Find out what this means for genomics, pharma, and platform rivals.
Can this A$653m raise turn PYC Therapeutics (ASX: PYC) into a global RNA frontrunner?
PYC Therapeutics is raising A$653M to fund four RNA therapies into human efficacy trials. Find out what this means for investors and the biotech sector.
Pneumococcal vaccine strategy shifts toward scale and integration with Vaxcyte Inc.’s VAX-31 Phase 3 push
Vaxcyte Inc. advances VAX-31 into pivotal trials. Find out what this means for vaccine competition, regulation, and long-term market positioning.
What’s driving GH Research’s stock spike? FDA IND verdict looms for lead depression candidate
GH Research is set to update investors on its FDA IND filing and Phase 3 launch plans for GH001. Find out what this means for its future in depression treatment.
Cynata Therapeutics (ASX: CYP) completes Phase 2 enrolment for CYP-001 as investors refocus on June 2026 data inflection
Cynata Therapeutics completes Phase 2 enrolment for CYP-001, shifting focus to June 2026 data. Read what this means for strategy, risk, and valuation.
Rigel Pharmaceuticals’ R289 delivers promising phase 1b results in transfusion-dependent MDS
Find out how Rigel Pharmaceuticals, Inc. is advancing R289 for lower-risk myelodysplastic syndrome with promising new phase 1b data—read the latest insights now!